Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 335

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 8
Chunk 335
---
 disclosures. 

F-8

3. Marketable Securities 

The following tables summarize the amortized cost and estimated fair value of the Company’s current and noncurrent marketable securities (in thousands):June 30, 2025AmortizedCost UnrealizedGainsUnrealizedLosses Fair ValueMarketable securities, current:U.S. Treasury securities$122,362 $112 $(14)$122,460 Commercial paper61,653 — (15)61,638 Government agency securities24,388 34 (6)24,416 Corporate debt13,076 — (4)13,072 Total marketable securities, current221,479 146 (39)221,586 Marketable securities, noncurrent:U.S. Treasury securities61,168 78 (1)61,245 Government agency securities13,455 2 (3)13,454 Total marketable securities, noncurrent74,623 80 (4)74,699 Total marketable securities$296,102 $226 $(43)$296,285 December 31, 2024Amortized Cost Unrealized Gain Unrealized Loss Fair Value Marketable securities, current:U.S. Treasury securities$55,154 $176 $— $55,330 Government agency securities31,198 62 (1)31,259 Corporate debt17,205 22 — 17,227 Commercial paper5,931 3 — 5,934 Total marketable securities, current109,488 263 (1)109,750 Marketable securities, noncurrent:U.S. Treasury securities15,266 83 — 15,349 Government agency securities5,133 23 — 5,156 Total marketable securities, noncurrent20,399 106 — 20,505 Total marketable securities$129,887 $369 $(1)$130,255 The Company has determined that there were no material changes in the credit risk, therefore the Company has not recognized any allowance for credit losses on its debt securities. As of June 30, 2025, the Company holds marketable securities with an aggregate fair value of $74.7 million that had remaining maturities between one and two years. All other securities had a contractual maturity of less than a year. There were no realized gains or losses during the three